Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/44006
IVERMECTIN: AN AWARD-WINNING DRUG WITH EXPECTED ANTIVIRAL ACTIVITY AGAINST COVID-19
COVID-19
SARS-CoV-2
Vírus da Síndrome Respiratória Aguda Grave
Antivirais
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Recife, PE, Brasil / University of Pernambuco. Graduate Program in Applied Cellular and Molecular Biology. Recife, PE, Brazil.
University of Miami. Department of Chemistry. Coral Gables, FL, USA.
University of Pernambuco. Institute of Biological Sciences. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil.
Federal Rural University of Pernambuco. Bioactive Compounds Synthesis Laboratory. Department of Chemistry. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia. Recife, PE, Brasil.
University of Miami. Department of Chemistry. Coral Gables, FL, USA.
University of Pernambuco. Institute of Biological Sciences. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil.
Federal Rural University of Pernambuco. Bioactive Compounds Synthesis Laboratory. Department of Chemistry. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia. Recife, PE, Brasil.
Abstract
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
Keywords in Portuguese
IvermectinaCOVID-19
SARS-CoV-2
Vírus da Síndrome Respiratória Aguda Grave
Antivirais
Share